Lotzniker M, Pavesi F, Scarabelli M, Vadacca G, Franchi M, Moratti R
Chemical-Clinical Analysis Service, IRCCS Policlinico S. Matteo, University of Pavia, Italy.
Int J Biol Markers. 1991 Apr-Jun;6(2):115-21. doi: 10.1177/172460089100600206.
CA 125 and CA 15.3 antigens were determined by enzyme immunoassay in 78 patients with ovarian cancer for a total of 540 determinations. The antigens were also investigated in sera from 100 women with other gynaecological diseases, 82 lung cancer patients and in 39 pleural fluids of varying origin. CA 15.3 reference values were evaluated in 91 healthy women (cut-off: 25 U/ml). CA 15.3 sensitivity at diagnosis (60%) and for detecting relapse (44%) was lower than that of CA 125 (90% and 64.7%, respectively). However, CA 15.3 does not increase with aspecific mesothelial cell reaction and thus it is more specific than CA 125. Combined use of the markers during follow-up improves early detection of relapse (at least one of the two was positive in 79% of cases). Therefore both CA 15.3 and CA 125 should be routinely determined for the detection and monitoring of ovarian cancer.
采用酶免疫分析法对78例卵巢癌患者进行了540次CA 125和CA 15.3抗原检测。还对100例患有其他妇科疾病的女性、82例肺癌患者的血清以及39份不同来源的胸液中的这些抗原进行了研究。对91名健康女性评估了CA 15.3的参考值（临界值：25 U/ml）。CA 15.3在诊断时的敏感性（60%）和检测复发时的敏感性（44%）低于CA 125（分别为90%和64.7%）。然而，CA 15.3不会因非特异性间皮细胞反应而升高，因此它比CA 125更具特异性。在随访期间联合使用这两种标志物可提高复发的早期检测率（79%的病例中两种标志物至少有一种呈阳性）。因此，为了检测和监测卵巢癌，应常规检测CA 15.3和CA 125。
